SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus
David A Hess, Daniella C Terenzi, Justin Z Trac, Adrian Quan, Tamique Mason, Mohammed Al-Omran, Deepak L Bhatt, Natasha Dhingra, Ori D Rotstein, Lawrence A Leiter, Bernard Zinman, Sandra Sabongui, Andrew T Yan, Hwee Teoh, C David Mazer, Kim A Connelly, Subodh Verma, David A Hess, Daniella C Terenzi, Justin Z Trac, Adrian Quan, Tamique Mason, Mohammed Al-Omran, Deepak L Bhatt, Natasha Dhingra, Ori D Rotstein, Lawrence A Leiter, Bernard Zinman, Sandra Sabongui, Andrew T Yan, Hwee Teoh, C David Mazer, Kim A Connelly, Subodh Verma
Abstract
Hess et al. quantified circulating aldehyde dehydrogenase-expressing (ALDHhi) cell subsets in people with T2DM given either empagliflozin (EMPA) or placebo. EMPA treatment increased circulating pro-angiogenic CD133+ progenitor cells, decreased pro-inflammatory ALDHhi granulocyte precursors, and increased ALDHhi monocytes with M2 polarization. EMPA treatment improved T2DM-associated "regenerative cell depletion" contributing to enhanced vascular health.
Copyright © 2019. Published by Elsevier Inc.
Source: PubMed